• MannKind completed patient randomization in its Phase 1b INFLO-1 trial of inhaled nintedanib DPI for idiopathic pulmonary fibrosis.
• Results have not been presented; a Phase 1b readout is slated for Q3 2026 to gauge early safety, tolerability, and drug exposure.
• The first patient entered the global Phase 2 INFLO-2 study, moving the program into mid-stage testing.
• INFLO-2 targets about 210 participants across about 85 sites worldwide, with initial enrollment reported in Windsor, Canada.
• The inhaled approach aims to deliver therapy to the lungs while reducing systemic side effects that can limit use of oral nintedanib.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606030605PRIMZONEFULLFEED9731146) on June 03, 2026, and is solely responsible for the information contained therein.